How do microtubule-targeted drugs work? An overview
- PMID: 18220533
- DOI: 10.2174/156800907783220417
How do microtubule-targeted drugs work? An overview
Abstract
The importance of microtubules in mitosis makes them a superb target for a group of highly successful, chemically diverse anticancer drugs. Knowledge of the mechanistic differences among the many drugs of this class is vital to understanding their tissue and cell specificity, the development of resistance, the design of novel improved drugs, optimal scheduling of treatment, and potential synergistic combinations. This overview covers microtubule assembly dynamics, the exquisite regulation of microtubule dynamics in cells by endogenous regulators, the important role of microtubule dynamics in mitosis, the diversity and number of microtubule-targeted drugs undergoing clinical development, the antimitotic mechanisms of microtubule-targeted drugs with emphasis on suppression of microtubule dynamics by vinblastine and taxol, the role of drug uptake and retention in the efficacy of microtubule-targeted drugs, and the anti-angiogenic and vascular-disrupting mechanisms of microtubule targeted drugs. In view of the success of this class of drugs, it has been argued that microtubules represent the single best cancer target identified to date, and it seems likely that drugs in this class will continue to remain an important chemotherapeutic class of drugs even as more selective chemotherapeutic approaches are developed.
Similar articles
-
Mechanism of action of antitumor drugs that interact with microtubules and tubulin.Curr Med Chem Anticancer Agents. 2002 Jan;2(1):1-17. doi: 10.2174/1568011023354290. Curr Med Chem Anticancer Agents. 2002. PMID: 12678749 Review.
-
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth.Mol Cancer Ther. 2005 Jul;4(7):1086-95. doi: 10.1158/1535-7163.MCT-04-0345. Mol Cancer Ther. 2005. PMID: 16020666
-
New microtubule/tubulin-targeted anticancer drugs and novel chemotherapeutic strategies.J Chemother. 2004 Nov;16 Suppl 4:83-5. doi: 10.1179/joc.2004.16.Supplement-1.83. J Chemother. 2004. PMID: 15688618 Review.
-
Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators.Cell Struct Funct. 1999 Oct;24(5):329-35. doi: 10.1247/csf.24.329. Cell Struct Funct. 1999. PMID: 15216890 Review.
-
Microtubules and Cell Division: Potential Pharmacological Targets in Cancer Therapy.Curr Drug Targets. 2023;24(11):889-918. doi: 10.2174/1389450124666230731094837. Curr Drug Targets. 2023. PMID: 37519203 Review.
Cited by
-
KML001 displays vascular disrupting properties and irinotecan combined antitumor activities in a murine tumor model.PLoS One. 2013;8(1):e53900. doi: 10.1371/journal.pone.0053900. Epub 2013 Jan 11. PLoS One. 2013. PMID: 23326531 Free PMC article.
-
A novel microtubule inhibitor, MT3-037, causes cancer cell apoptosis by inducing mitotic arrest and interfering with microtubule dynamics.Am J Cancer Res. 2016 Mar 15;6(4):747-63. eCollection 2016. Am J Cancer Res. 2016. PMID: 27186428 Free PMC article.
-
Mitotic cell death induction by targeting the mitotic spindle with tubulin-inhibitory indole derivative molecules.Oncotarget. 2017 Mar 21;8(12):19738-19759. doi: 10.18632/oncotarget.14980. Oncotarget. 2017. PMID: 28160569 Free PMC article.
-
The microtubule poison vinorelbine kills cells independently of mitotic arrest and targets cells lacking the APC tumour suppressor more effectively.J Cell Sci. 2012 Feb 15;125(Pt 4):887-95. doi: 10.1242/jcs.091843. Epub 2012 Mar 7. J Cell Sci. 2012. PMID: 22399804 Free PMC article.
-
Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells.J Med Chem. 2014 Oct 9;57(19):7916-32. doi: 10.1021/jm5009902. Epub 2014 Sep 26. J Med Chem. 2014. PMID: 25211704 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
